|
1
|
The effectiveness and cost-effectiveness of minimal access surgery amongst people with gastro-oesophageal reflux disease - a UK collaborative study. The REFLUX trial.
|
Health Technol Assess
|
2008
|
2.68
|
|
2
|
Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
|
Health Technol Assess
|
2006
|
1.29
|
|
3
|
Clinical effectiveness and cost-effectiveness of tests for the diagnosis and investigation of urinary tract infection in children: a systematic review and economic model.
|
Health Technol Assess
|
2006
|
1.22
|
|
4
|
Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
|
Health Technol Assess
|
2011
|
1.16
|
|
5
|
Prenatal screening and treatment strategies to prevent group B streptococcal and other bacterial infections in early infancy: cost-effectiveness and expected value of information analyses.
|
Health Technol Assess
|
2007
|
1.15
|
|
6
|
Clinical and economic evaluation of laparoscopic surgery compared with medical management for gastro-oesophageal reflux disease: 5-year follow-up of multicentre randomised trial (the REFLUX trial).
|
Health Technol Assess
|
2013
|
0.96
|
|
7
|
Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.
|
Health Technol Assess
|
2012
|
0.92
|
|
8
|
Cost-effectiveness of laparoscopic fundoplication versus continued medical management for the treatment of gastro-oesophageal reflux disease based on long-term follow-up of the REFLUX trial.
|
Br J Surg
|
2013
|
0.79
|
|
9
|
Golimumab for the treatment of psoriatic arthritis.
|
Health Technol Assess
|
2011
|
0.75
|